LCAA,L Catterton Asia Acquisition Corp | Financials

Financials

LCAA

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

L Catterton Asia Acquisition CorpLCAA

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

L Catterton Asia Acquisition Corp does not have significant operations.

It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.

It focuses on acquiring business in the consumer technology sectors in Asia. L Catterton Asia Acquisition Corp was incorporated in 2021 and is headquartered in Singapore.

Latest News >

Boeing Says Departing Chief Executive Received $32.8 Million Pay Package in 2023

Apr 8, 2024

08:21 AM EDT, 04/08/2024 (MT Newswires) -- Boeing's ( BA ) departing Chief Executive David Calhoun received a total compensation of about $32.8 million in 2023, up from his $22.6 million pay package in 2022, according to a regulatory filing Friday. Calhoun, who announced his resignation from the company in March amid concerns about Boeing ( BA ) planes' quality,...

Arthur Hayes Offloads 237K GMX After 2 Years, Here’s His Profit: Data

Apr 8, 2024

Arthur Hayes, founder and former CEO of the crypto exchange BitMEX, has unstaked and offloaded more than 237,000 GMX, the native tokens of perpetual crypto futures decentralized exchange GMX, which has been in his possession since March 2022. According to a tweet by market analysis platform Lookonchain, Hayes transferred the tokens to a new address linked to crypto algorithmic trading...

Blackstone to take Apartment Income REIT private for $10 bln, WSJ reports

Apr 8, 2024

April 8 (Reuters) - Asset manager Blackstone is taking private rental housing firm Apartment Income REIT ( AIRC ) , known as AIR Communities, for $10 billion in cash, the Wall Street Journal reported on Monday, citing people familiar with the matter. (Reporting by Ananta Agarwal in Bengaluru; Editing by Arun Koyyur) ...

$Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma$

Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma

Apr 8, 2024

08:22 AM EDT, 04/08/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) and Legend Biotech ( LEGN ) said the US Food and Drug Administration has approved Carvykti to treat adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. In 2017, Legend entered into a worldwide license and collaboration agreement with...